(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.
EJNMMI Res
; 6(1): 46, 2016 Dec.
Article
en En
| MEDLINE
| ID: mdl-27246327
ABSTRACT
BACKGROUND:
Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients.METHODS:
Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of (18)F-uptake.RESULTS:
The inter- and intra-individual variations in (18)F-uptake (SUVA50%) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and (18)F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from -2.20 to 4.53.CONCLUSIONS:
Iliac (18)F-uptake was associated with the local MAR in myeloma patients. Furthermore, (18)F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2016
Tipo del documento:
Article